Jimmy Li

Dr. Jimmy Li

University of Sherbrooke
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
JLJimmy Li
Jimmy Li
CDCharles Deacon
Charles Deacon
MKMark Robert Keezer
Mark Robert Keezer
A bibliometric analysis (BA) is a knowledge synthesis methodology aimed at quantitively summarizing large amounts of bibliometric data. We aimed to summarize the performance of BAs in the health sciences. We searched Scopus for BAs in the health sciences published prior to May 10th, 2023. All identified studies were included. We performed a BA on these studies in two steps: performance analysis and science mapping. For the performance analysis, various indicators of scientific production were calculated using the bibliometrix R package. For the science mapping, VOSviewer was used to generate a co-authorship network and a keyword co-occurrence network. In total, 5828 BAs were analyzed. Scientific production has exploded in the last years, with more than 1500 BAs published in 2022 alone. Scientific impact (i.e., citations) has also been rising, although at a lesser pace. The mean number of citations per year per BA was 1.78. China was the most productive country, publishing more BAs than the nine other most productive countries combined. China paradoxically had a lower number of citations per publication compared with the nine other most productive countries. International collaborations were rare. Common BA themes included oncology, public health, neurosciences, mental health, artificial intelligence, and COVID-19. BAs are increasingly common in the health sciences, but their performance remains limited. More international collaborations and standardized guidelines could help improve their performance, notably the frequency at which they are cited.

18 January 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JLJimmy Li
Jimmy Li
SRSandra Reiter-Campeau
Sandra Reiter-Campeau
DNDina Namiranian
Dina Namiranian
DTDènahin Hinnoutondji Toffa
Dènahin Hinnoutondji Toffa
ABAlain Bouthillier
Alain Bouthillier
DNDang Khoa Nguyen
Dang Khoa Nguyen
Background: Epilepsy surgery failure is not uncommon, with several explanations having been proposed. In this series, we detail cases of epilepsy surgery failure subsequently attributed to insular involvement. Methods: We retrospectively identified patients investigated at the epilepsy monitoring units of two Canadian tertiary care centers (2004–2020). Included patients were adults who had undergone epilepsy surgeries with recurrence of seizures post-operatively and who were subsequently determined to have an insular epileptogenic focus. Clinical, electrophysiological, neuroimaging, and surgical data were synthesized. Results: We present 14 patients who demonstrated insular epileptic activity post-surgery-failure as detected by intracranial EEG, MEG, or seizure improvement after insular resection. Seven patients had manifestations evoking possible insular involvement prior to their first surgery. Most patients (8/14) had initial surgeries targeting the temporal lobe. Seizure recurrence ranged from the immediate post-operative period to one year. The main modality used to determine insular involvement was MEG (8/14). Nine patients underwent re-operations that included insular resection; seven achieved a favorable post-operative outcome (Engel I or II). Conclusions: Our series suggests that lowering the threshold for suspecting insular epilepsy may be necessary to improve epilepsy surgery outcomes. Detecting insular epilepsy post-surgery-failure may allow for re-operations which may lead to good outcomes.

27 July 2023 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
JLJimmy Li
Jimmy Li
JKJoudy Kabouji
Joudy Kabouji
SBSarah Bouhadoun
Sarah Bouhadoun
STSarah Tanveer
Sarah Tanveer
KFKristian B. Filion
Kristian B. Filion
MKMark Robert Keezer
Mark Robert Keezer

16 January 2025 in Epilepsia
Verified
Journal Article
Open access
RBRenaud Balthazard
Renaud Balthazard
RDRose‐Marie Drouin‐Engler
Rose‐Marie Drouin‐Engler
SBSamuel Bertrand
Samuel Bertrand
FZFaycal Zine‐Eddine
Faycal Zine‐Eddine
JLJimmy Li
Jimmy Li
CLCatherine Larochelle
Catherine Larochelle
Objective: Tuberous sclerosis complex (TSC) is a monogenetic disorder associated with sustained mechanistic target of rapamycin (mTOR) activation, leading to heterogeneous clinical manifestations. Epilepsy and renal angiomyolipoma are the most important causes of morbidity in adult people with TSC (pwTSC). mTOR is a key player in inflammation, which in turn could influence TSC‐related clinical manifestations. Reliable biomarkers are lacking to monitor and predict evolution and response to treatment for epilepsy in pwTSC. Inflammation has been implicated in epileptogenesis in non–TSC‐related epilepsy. We aimed to characterize the relation between markers of neuroglial activation/injury, markers of peripheral inflammation, and active epilepsy in pwTSC to identify accessible biomarkers and potential new therapeutic targets.Methods: We performed a cross‐sectional study to investigate markers of central nervous system (CNS) (neurofilament light [NfL] and glial fibrillary acidic protein [GFAP]) and peripheral (45 cytokines) inflammation in the peripheral blood of pwTSC (n = 46) vs age‐ and sex‐matched healthy controls (HCs) (n = 26). In pwTSC, markers associated with active epilepsy (n = 23/46) were compared to non‐TSC epilepsy controls (n = 18). Observations on markers of neuroglial activation/injury (GFAP, NfL) were confirmed in an independent TSC cohort (n = 45; 69% with active epilepsy).Results: We report that TSC is characterized by elevated serum levels of marker of astrogliosis (GFAP), pro‐inflammatory molecules (interleukin 1β [IL‐1β], CXCL8) and trophic factor (epidermal growth factor [EGF]) compared to HCs and to non–TSC‐related epilepsy controls. Among pwTSC, renal angiomyolipoma presence and size was associated with IL‐15. It is notable that active epilepsy in pwTSC was associated with higher levels of GFAP compared to pwTSC without epilepsy, which was confirmed in an external validation cohort, and with elevated levels of pro‐inflammatory cytokines (IL‐17A, IL‐17C, tumor necrosis factor α [TNF‐α]), not significantly related to seizure activity or treatment with mTOR inhibitor. These associations remained significant after adjusting for age and sex.Significance: These results suggest that key inflammatory mediators could contribute to epileptogenesis and represent novel biomarkers and therapeutic targets in TSC.

10 May 2022 in Neurology
Verified
Journal Article
Closed access
PDF file
JLJimmy Li
Jimmy Li
LLLawrence Ledoux-Hutchinson
Lawrence Ledoux-Hutchinson
DTDènahin Hinnoutondji Toffa
Dènahin Hinnoutondji Toffa
Background and Objectives: This systematic review with meta-analysis (PROSPERO: CRD42021249336) was performed to estimate the pooled lifetime prevalence of bipolar symptoms (BS) and bipolar disorder (BD) in people with epilepsy (PWE). Methods: A search was performed on June 5th, 2021, in four databases (MEDLINE/PubMed, Ovid EMBASE, Ovid APA PsycInfo, and Web of Science) for original research reporting on BS/BD in PWE, with no restriction on language or time of publication. Inclusion criteria were as follows: 1) original research, 2) cross-sectional study design component, 3) reported a lifetime prevalence of BS/BD or enough information to calculate an estimate, and 4) reported the method by which participants were deemed bipolar. Studies based on an exclusively pediatric population were excluded. To calculate pooled lifetime prevalence of BS/BD, two meta-analytic random-effects models were fitted, one for BS, and the other for BD. Risk of bias was assessed using a standardized appraisal tool for studies reporting prevalence. Certainty of evidence was evaluated using the GRADE approach. Results: A total of 750 records were screened, and 17 studies were included for analysis: seven provided prevalence estimates for only BS, eight for only BD, and two for both BS and BD. After outlier exclusion and subgroup analysis using screening method as a moderator, the pooled prevalence of BS in PWE was 12.3% [95% CI; 10.6-14.1%] (7,506 PWE). The pooled prevalence of BD in PWE was 4.5% [95% CI; 2.2-7.4%] (48,334 PWE). Considerable heterogeneity was present – more so for BD than for BS – and could be explained through differences in population demographics and study methodology. Discussion: This study’s main limitation was regarding the certainty of evidence. Notwithstanding, our estimates of prevalence should prompt further research on BS/BD in PWE. Given the significant morbidity associated to BD, clinicians should carefully screen PWE for BS.

14 February 2024 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
\A\R\Nrachelle Abi-Nahed
\R\Nrachelle Abi-Nahed
JLJimmy Li
Jimmy Li
JCJasmine Carlier
Jasmine Carlier
VBVéronica Birca
Véronica Birca
ABArline-Aude Bérubé
Arline-Aude Bérubé
DNDang Khoa Nguyen
Dang Khoa Nguyen
Objective: To study the outcome of patients with psychogenic non-epileptic seizures (PNES) after their diagnosis in the epilepsy monitoring unit (EMU).Methods: Patients diagnosed in our EMU with definite PNES between January 2009 and May 2023 were contacted by phone, and those who agreed to participate were asked a set of predetermined questions. Comparative analyses were carried out on several variables before and after diagnosis: number of participants with daily PNES, number of visits to the emergency department, number of participants who consulted their general practitioner or a neurologist outside of a scheduled follow-up, number of participants who took antiseizure medications (ASMs) or psychotropic drugs, and employment status.Results: Out of the 103 patients with a definite diagnosis of PNES, 61 patients (79% female) accepted to participate in our study. The median age at PNES onset was 35 years, and the median delay to diagnosis was 3 years. Almost two-thirds (62%) were receiving ASMs and 40% psychotropic drugs. The mean stay at the EMU was 5 days. PNES diagnosis was explained to almost all patients (97%) by the end of their EMU stay and was well-accepted by most (89%). When contacted, 46% of participants no longer had PNES; 32% mentioned that their PNES had ceased immediately upon communication of the diagnosis. The median follow-up duration was 51 months. Fewer patients had daily seizures after the diagnosis (18 vs. 38%; p < 0.0455). Similarly, the median number of emergency department visits was significantly lower (0 vs. 2; p < 0.001). Only 17 patients consulted their general practitioner (vs. 40, p < 0.001) and 20 a neurologist (vs. 55, p < 0.001) after a PNES attack outside of a scheduled follow-up. The use of ASMs was also significantly reduced from 70 to 33% (p < 0.01), with only one still taking an ASM for its antiseizure properties. Significantly more participants were working at last follow-up than at PNES diagnosis (49 vs. 25%; p < 0.001).Conclusion: Our study revealed a relatively favorable long-term outcome of definite PNES diagnosed in the EMU that translated in significant reductions in PNES frequency, health care utilization and ASM use, as well as a significant increase in employment rate.